BIOREGENX, INC. (BRGX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
---|---|---|---|---|
Medical testing | - | 48,533 [1] | - | - |
Nutritional | - | 467,531 [1] | - | - |
Other sales | - | 416 [1] | - | - |
Wellness devices | - | 10 [1] | - | - |
Customers and direct sales | - | 264,874 [2] | - | - |
Medical and academic | - | 167,688 [2] | - | - |
Reseller | - | 83,928 [2] | - | - |
Net sales | 445,970 | 515,147 | 596,037 | 734,032 |
Cost of sales | 93,514 | 109,116 | 114,389 | 264,154 |
Gross profit | 352,456 | 406,031 | 481,648 | 469,878 |
Distributors incentives | - | - | - | 112,588 |
Amortization expense | - | - | 562,089 | 562,089 |
Selling, general and administrative (including equity compensation granted to officers, directors and contractors of 173,106 in the period ended june 30, 2025 and 2,512,706 in the period ended june 30, 2024) | 456,728 | 590,368 | 236,279 | 834,998 |
Distributors incentives | 2,987 | 8,278 | 10,587 | - |
Total operating expenses | 459,715 | 598,646 | 808,955 | 1,509,675 |
Loss from operations | -107,259 | -192,615 | -327,307 | -1,039,797 |
Interest expense and financing costs (including related party interest of 35,455 in the six months ended in june 30, 2025 and 31,063 in june 30, 2024 | 71,086 | - | - | - |
Interest expense and financing costs (including related party interest of 35,455 in the three months ended in march 31, 2025 and 31,063 in march 31, 2024 | - | 74,239 | 67,553 | 66,331 |
Nonoperating income (expense) | - | - | -67,553 | -66,331 |
Net loss | -178,345 | -266,854 | -394,860 | -1,106,128 |
Foreign currency translation adjustment | -7,197 | -2,059 | -2,561 | 518 |
Other comprehensive loss | -185,542 | -268,913 | -397,421 | -1,105,610 |
Loss per share - basic | - | - | - | - |
Loss per share - diluted | - | - | - | - |
Weighted average common shares outstanding - basic | 959,205,422 | 956,994,100 | 956,530,100 | 956,530,100 |
Weighted average common shares outstanding - diluted | 959,205,422 | 956,994,100 | 956,530,100 | 956,530,100 |